Venus Medtech honored as Best Pharmaceutical and Medical Company

On January 6, 2021, Venus Medtech-B (02500) was awarded “Best Pharmaceutical and Medical Company” at the 5th Golden Hong Kong Stocks Awards Ceremony in Shenzhen.

The 5th Golden Hong Kong Stocks Awards Ceremony was jointly organized by Zhitong Caijing and Tonghuashun Finance, leading Hong Kong and US stock information platforms in China, with roadshow support from Road showing, a professional financial roadshow live stream platform.

The "Best Pharmaceutical and Medical Company" award aims to honor HK-listed pharmaceutical and medical enterprises marked by effective corporate governance structure, prominent industry position, and satisfactory main business performance that provide sustainable and stable returns for investors. That the award was granted to Venus Medtech underlines the interests and attention of the healthcare industry and investors to innovative medical devices. It is both a great encouragement and a spur to the company.

The 5th Golden Hong Kong Stocks Awards underwent a rigorous selection spanning over two months. More than 1,000 HK-listed companies registered for the event. The candidates are engaged in both traditional industries such as energy, finance, automobile and manufacturing, and emerging industries that lead the transformation of the Chinese economy, such as telecommunications, semiconductor, Internet technology and healthcare. The participants boast a total worth of more than 20 trillion HKD, amounting to more than 1/2 of the entire Hong Kong stock market. In addition, more than 90% of the enterprises are included in Mainland-Hong Kong Stock Connect programs.

More than 200 banks, securities, insurers, trusts, capital managers and other financial institutions as well as thousands of professional investors attended the event. The awardees were determined by a judging panel based on their performance growth, industry ranking, corporate governance, business model, market influence, and capital market performance over the past year as well as public votes.

Prev:Venus Medtech acquires Nuocheng Medical for comprehensive cardiac device innovation platfo···

Next:VenusA-Plus retrievable transcatheter aortic valve replacement system obtains quick approv···